TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03415126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007: ascending doses
Description: Oral drug for the treatment of advanced solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007 RD
Description: Oral drug for the treatment of advanced solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007 RD
Description: Oral drug for the treatment of advanced solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007 RD
Description: Oral drug for the treatment of advanced solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007 RD
Description: Oral drug for the treatment of advanced solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007 RD
Description: Oral drug for the treatment of advanced solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007 RD
Description: Oral drug for the treatment of advanced solid tumors
Study: NCT01899625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Weight Loss (BWL)
Description: 12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivation Enhanced BWL
Description: 12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
Study: NCT01447368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical total parathyroidectomy with forearm autografting
Description: Surgical total parathyroidectomy with forearm autografting will be performed
Study: NCT02199600

Intervention type: DEVICE
Group type: OTHER
Intervention: GMK Sphere Knee Replacement
Study: NCT04261569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ev-NIRT
Description: Endoventricular near infra red treatment : Intraventricular pulsed, chronic, cyclic, near-infrared illumination of the Central Nervous System (CNS) at 150 Hz, 15 mW, 1 minute ON and 5 minutes OFF
Study: NCT04575025

Intervention type: DRUG
Intervention: Tabrecta tablets
Description: There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT02042430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT03738969

Intervention type: PROCEDURE
Intervention: Laparotomic radical hysterectomy
Description: Radical hysterectomy applied by laparotomy

Intervention type: PROCEDURE
Intervention: Laparoscopic radical hysterectomy
Description: Radical hysterectomy applied by laparoscopic
Study: NCT00564785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera(TM)
Description: Synera(TM) patch applied 20 minutes prior to epidural

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch applied 20 minutes prior to epidural
Study: NCT02150499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol tartrate HFA inhalation aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol tartrate HFA inhalation aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03371758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
Study: NCT02887872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation-dynamic hand orthosis
Description: Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
Study: NCT04505904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon
Description: Synthetic oxytocin spray, 24 IU per spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: Synthetic oxytocin spray, 24 IU per spray.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo spray with no active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo spray with no active ingredient.
Study: NCT04052529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary self-monitoring
Description: Participants use a popular smartphone application to track their food and drink intake for one month.
Study: NCT00767364

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Description: Oral vaccine for prevention of rotavirus infection, 3 dose series

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Description: Oral vaccine for prevention of rotavirus infection, 3 dose series
Study: NCT03892512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol Hydrochloride
Description: Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )
Study: NCT01063829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg AIC246
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg AIC246
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 240 mg AIC246
Description: Oral administration

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral administration
Study: NCT02783131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedNav
Description: MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
Study: NCT03447366

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mitral doppler
Description: Mitral doppler before and after vascular filling
Study: NCT01122576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crystalens AO
Description: Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR
Description: ReSTOR surgically implanted bilaterally. Study observation up to 180 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis Multifocal IOL
Description: Tecnis surgically implanted bilaterally. Study observation up to 180 days.
Study: NCT03274583

Intervention type: DIAGNOSTIC_TEST
Intervention: Smartphone seismographic recording
Description: A short recording of heart rhythm using a smartphone.
Study: NCT01829360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (interactive book reading, dialogic reading, shared book reading)
Description: Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (interactive book reading, dialogic reading, shared book reading)
Description: Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (interactive book reading, dialogic reading, shared book reading)
Description: Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (interactive book reading, dialogic reading, shared book reading)
Description: Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
Study: NCT06416735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours
Study: NCT02066623

Intervention type: DEVICE
Intervention: ABSORB Scaffold
Description: Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
Study: NCT03471936

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acquisition of pressure-volume-loops
Description: Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
Study: NCT02061605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Tissue Welding Device
Description: Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
Study: NCT02032602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Dry Needling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling
Study: NCT04714528

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: Physical exercise as described before.

Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation Therapy
Description: Relaxation therapy as described before.
Study: NCT03640468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine full dose
Description: This group will receive induction of anesthesia using Ketamine 1 mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine half dose
Description: This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: This group will receive lidocaince 1 mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: This group will receive midazolam 0.05 mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This group will receive midazolam 0.05 mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: This group will receive normal saline 10 mL
Study: NCT02693782

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 g/day maltodextrin in 3 portions of 5 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fibre supplement
Description: 15 g/day Wheat Bran Extract in 3 portions of 5 g.
Study: NCT04564144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine Hydrochloride
Description: A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
Study: NCT02690220

Intervention type: DEVICE
Group type: OTHER
Intervention: TiLOOP® PRO Plus A
Description: The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
Study: NCT03635814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YD312 50mg
Description: YD312 50mg \* 1 + placebo 6 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YD312 150mg
Description: YD312 50mg \* 3 + placebo 6 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YD312 350mg
Description: YD312 50mg \* 7 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: YD312 0mg \* 7 tabets
Study: NCT04635566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
Description: mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one time/day at the evening.
Study: NCT01132612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A 150 mg powder for solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A 150 mg powder for solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A 150 mg powder for solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to AIN457A 150 mg powder for solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to AIN457A 150 mg powder for solution
Study: NCT03610399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Different total dose and supervision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Different total dose and supervision.

Intervention type: DRUG
Group type: OTHER
Intervention: Primaquine
Description: Different total dose and supervision.
Study: NCT02252536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin enacarbil
Description: Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
Study: NCT04048590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skilled Nursing Facility at Home
Description: We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
Study: NCT02941874

Intervention type: OTHER
Intervention: Blood sample collection during an OGTT to assess IRAP blood concentration
Description: Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
Study: NCT04060563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSPIRSTAR IS02 MICROCURRENT STIMULATOR
Description: Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: INSPIRSTAR IS02 MICROCURRENT STIMULATOR
Description: Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes.
Study: NCT04351763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Ion channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Ion channel blocker
Study: NCT02676388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freeze-dried, Capsulized FMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh FMT
Study: NCT04720404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help mindfulness/compassion exercises
Description: Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support as usual
Description: Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support as usual
Description: Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
Study: NCT01159613

Intervention type: OTHER
Intervention: Responders
Description: Responders

Intervention type: OTHER
Intervention: Non Responders
Description: Non Responders
Study: NCT01936909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (weeks 1-2)
Description: Anakinra 100 mg daily for weeks 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (weeks 1-2)
Description: Anakinra 100 mg daily for weeks 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (weeks 3-12)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo